Indy Hematology Review
M

Indy Hematology Review 2023: Plasma Cell Neoplasms and Amyloidosis Updates

By Indy Hematology Review FEATURING Morie Gertz
April 19, 2023
0 Comments
Login to view comments. Click here to Login

Featured Video

14:41
Sanofi

Efficacy and Safety of a Treatment Option for Adults with Multiple M…

Feat. J. Mikhael

Featured Video

15:18
Treatment Considerations in CLL: Challenging Patient Cases

Treatment Considerations for Ibrutinib-Intolerant Patients - A Patie…

Feat. M. Shadman

Related Content

AUTOPLAY
18:26
William Schaffner

Shingles (Herpes Zoster) Vaccination in Adults: What is the Importan…

20:19
Insights from 2023 ASCO® Annual Meeting

ASCO® 2023 Insights: "Highlights of Hematologic Malignancies - …

Feat. A. Paulus
13:43
Houston Methodist Hospital

Lung Involvement in Amyloidosis

Feat. H. Huang
31:51
Indy Hematology Review

Treating Multiple Myeloma: The Cure Is Within Reach - Goals of Curre…

Feat. K. Anderson
03:17
Insights from 2023 IMS Annual Meeting

IMS 2023 Insights: "Highlights From the International Myeloma S…

Feat. J. Richter
05:56
ASH 2022 Conference Coverage

ASH 2022 Myeloma XI Trial: Defining the Optimal Duration of Lenalido…

Feat. G. Morgan
13:18
Insights from 2023 IMS Annual Meeting

Highlights and Key Takeaways From the 2023 International Myeloma Soc…

Feat. A. Jakubowiak
44:49
Dana-Farber Cancer Institute

Recent Updates in Multiple Myeloma

Feat. K. Anderson
32:03
Indy Hematology Review

Emerging and Current Treatment of MM: What Should We Know and What S…

Feat. K. Anderson
13:36
Vanderbilt University Medical Center (VUMC)

Venous Thromboembolism Prophylaxis in Newly Diagnosed MM

Feat. M. Baljevic
40:21
Fred Hutch 13th Annual Comprehensive Hematology & Oncology Review Course

Overview of Hematopoietic Cell Transplantation

Feat. R. Salit
04:31
ASH 2022 Conference Coverage

ASH 2022 GRIFFIN Trial Final Analysis: D-RVd in Clinically Relevant …

Feat. A. Chari
52:39
Yale Cancer Center

Myeloma in 2023: So Many Drugs, Yet So Few Cures

Feat. A. Chari
18:27
Indy Hematology Review

DEBATE: Why Not to Transplant When MRD Has Been Achieved After Initi…

Feat. J. Mikhael
06:11
Insights from 2023 EHA® Annual Meeting

EHA® 2023 Insights: "An Outpatient Model for Teclistamab Step-U…

Feat. A. Varshavsky-Yanovsky
30:59
Houston Methodist Hospital

Overview of Advances in Multiple Myeloma

Feat. S. Ganguly
26:52
Penn Medicine Cellicon Valley '23: The Future of Cell and Gene Therapies

Bispecifics in Multiple Myeloma

Feat. P. Mangan
21:11
MyCancerHaven

Experts Discuss the Future of Stem Cell Transplantation in Myeloma

Feat. R. Vij, N. Callander
17:34
Penn Medicine Cellicon Valley '23: The Future of Cell and Gene Therapies

Overview and Updates in CAR-T for Multiple Myeloma

Feat. E. Stadtmauer
26:24
Dana-Farber Cancer Institute

Myeloma 101: Diagnosis, Prognosis & Risk

Feat. N. Munshi